Sign In
Buy FENC
$9.14
-0.84 (-8.42%)
At Close: Jun 03, 2026
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
06:00am, Thursday, 09'th Sep 2021
RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a uni
Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
06:00am, Tuesday, 10'th Aug 2021
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~
Fennec Announces Results of Annual Meeting
05:30pm, Tuesday, 29'th Jun 2021
RESEARCH TRIANGLE PARK, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy
Fennec Pharmaceuticals: The PEDMARK NDA Has Been Accepted, We Remain Bullish On The November PDUFA Catalyst
06:00pm, Thursday, 24'th Jun 2021
The CRL manufacturing issue has been resolved and the PEDMARK NDA has been accepted. The wait has been very long, but a PDUFA action date of November 27 has been set, and we think this will be a meani
Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility
06:00am, Thursday, 24'th Jun 2021
RESEARCH TRIANGLE PARK, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a uniqu
Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity
07:17am, Tuesday, 22'nd Jun 2021
The FDA has accepted for review Fennec Pharmaceuticals Inc's (NASDAQ: FENC) resubmitted marketing application seeking approval for Pedmark (formulated sodium thiosulfate) to prevent ototoxicity ind
Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™
06:00am, Tuesday, 22'nd Jun 2021
~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~
Fennec Pharma Refiles Pedmark US Application For Cisplatin-Induced Ototoxicity In Pediatric Patients
08:34am, Friday, 28'th May 2021
Fennec Pharmaceuticals Inc (NASDAQ: FENC) has resubmitted its marketing application to the FDA seeking approval for Pedmark (formulated sodium thiosulfate) for the prevention of ototoxicity (toxic
5 Pre-Market Stock Gainers For May 28: VTNR, ITRM, MTEX, AMC, FENC
07:40am, Friday, 28'th May 2021
Here is an overview of 5 of the top stock gainers for May 28 during pre-market and why the stock prices moved. The post 5 Pre-Market Stock Gainers For May 28: VTNR, ITRM, MTEX, AMC, FENC appeared firs
Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for PEDMARK™
06:00am, Friday, 28'th May 2021
~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for
Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
06:00am, Thursday, 13'th May 2021
~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~
ScPharmaceuticals: The Third Time's A Charm
09:11am, Wednesday, 12'th May 2021
ScPharmaceuticals: The Third Time's A Charm
Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update
06:00am, Tuesday, 30'th Mar 2021
~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~
Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
07:02am, Monday, 16'th Nov 2020
~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™ ~
New York, New York--(Newsfile Corp. - November 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FE
